0001209191-19-056038.txt : 20191112
0001209191-19-056038.hdr.sgml : 20191112
20191112163828
ACCESSION NUMBER: 0001209191-19-056038
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191112
FILED AS OF DATE: 20191112
DATE AS OF CHANGE: 20191112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Manning Paul B
CENTRAL INDEX KEY: 0001494695
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38135
FILM NUMBER: 191210181
MAIL ADDRESS:
STREET 1: 200 GARRETT STREET SUITE S
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001685071
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813858961
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
BUSINESS PHONE: 919-806-4487
MAIL ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
FORMER COMPANY:
FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20160919
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-12
1
0001685071
Dova Pharmaceuticals Inc.
DOVA
0001494695
Manning Paul B
200 GARRETT STREET, SUITE S
CHARLOTTESVILLE
VA
22902
1
0
1
0
Common Stock
2019-11-12
4
U
0
12979016
27.50
D
0
D
Common Stock
2019-11-12
4
U
0
1783226
27.50
D
0
I
By LLC
Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship.
These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
/s/ Mark Ballantyne, Attorney-in-Fact
2019-11-12